» Articles » PMID: 32815547

Epigenetic Modification and Therapeutic Targets of Diabetes Mellitus

Overview
Journal Biosci Rep
Specialty Cell Biology
Date 2020 Aug 21
PMID 32815547
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of diabetes and its related complications are increasing significantly globally. Collected evidence suggested that several genetic and environmental factors contribute to diabetes mellitus. Associated complications such as retinopathy, neuropathy, nephropathy and other cardiovascular complications are a direct result of diabetes. Epigenetic factors include deoxyribonucleic acid (DNA) methylation and histone post-translational modifications. These factors are directly related with pathological factors such as oxidative stress, generation of inflammatory mediators and hyperglycemia. These result in altered gene expression and targets cells in the pathology of diabetes mellitus without specific changes in a DNA sequence. Environmental factors and malnutrition are equally responsible for epigenetic states. Accumulated evidence suggested that environmental stimuli alter the gene expression that result in epigenetic changes in chromatin. Recent studies proposed that epigenetics may include the occurrence of 'metabolic memory' found in animal studies. Further study into epigenetic mechanism might give us new vision into the pathogenesis of diabetes mellitus and related complication thus leading to the discovery of new therapeutic targets. In this review, we discuss the possible epigenetic changes and mechanism that happen in diabetes mellitus type 1 and type 2 separately. We highlight the important epigenetic and non-epigenetic therapeutic targets involved in the management of diabetes and associated complications.

Citing Articles

Diabetes-related cognitive impairment: Mechanisms, symptoms, and treatments.

Yu X, He H, Wen J, Xu X, Ruan Z, Hu R Open Med (Wars). 2025; 20(1):20241091.

PMID: 39822993 PMC: 11737369. DOI: 10.1515/med-2024-1091.


Programmed BRD9 Degradation and Hedgehog Signaling Activation via Silk-Based Core-Shell Microneedles Promote Diabetic Wound Healing.

Liu Y, Zhou M, Sun J, Yao E, Xu J, Yang G Adv Sci (Weinh). 2024; 11(45):e2404130.

PMID: 39413023 PMC: 11615742. DOI: 10.1002/advs.202404130.


Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?.

Odimegwu C, Uwaezuoke S, Chikani U, Mbanefo N, Adiele K, Nwolisa C Diabetes Metab Syndr Obes. 2024; 17:3557-3576.

PMID: 39323929 PMC: 11423826. DOI: 10.2147/DMSO.S479077.


miRNA and leptin signaling in metabolic diseases and at extreme environments.

Mondal S, Rathor R, Singh S, Suryakumar G Pharmacol Res Perspect. 2024; 12(4):e1248.

PMID: 39017237 PMC: 11253706. DOI: 10.1002/prp2.1248.


AMPK pathway: an emerging target to control diabetes mellitus and its related complications.

Kakoti B, Alom S, Deka K, Halder R J Diabetes Metab Disord. 2024; 23(1):441-459.

PMID: 38932895 PMC: 11196491. DOI: 10.1007/s40200-024-01420-8.


References
1.
Butler P, Elashoff M, Elashoff R, Gale E . A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care. 2013; 36(7):2118-25. PMC: 3687282. DOI: 10.2337/dc12-2713. View

2.
Wallace C, Smyth D, Maisuria-Armer M, Walker N, Todd J, Clayton D . The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat Genet. 2009; 42(1):68-71. PMC: 2820243. DOI: 10.1038/ng.493. View

3.
Dayeh T, Ling C . Does epigenetic dysregulation of pancreatic islets contribute to impaired insulin secretion and type 2 diabetes?. Biochem Cell Biol. 2015; 93(5):511-21. DOI: 10.1139/bcb-2015-0057. View

4.
Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

5.
Cedar H, Bergman Y . Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009; 10(5):295-304. DOI: 10.1038/nrg2540. View